Free tool
FAERS Monitor: Axtle
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 210661 or its brand name (Axtle, Pemetrexed Dipotassium). Reports on generic versions are filed under their own applications.
Reports
22,302
Serious
21,858
98% of reports
Hospitalization
10,318
Death reported
3,873
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- malignant neoplasm progression1,726
- anaemia1,313
- disease progression1,147
- off label use1,130
- nausea1,071
- neutropenia1,071
- diarrhoea1,041
- pancytopenia1,010
- thrombocytopenia997
- drug ineffective983
- acute kidney injury840
- vomiting823
- pneumonia800
- febrile neutropenia799
- death797
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 36 |
| 2005 | 42 |
| 2006 | 17 |
| 2007 | 83 |
| 2008 | 123 |
| 2009 | 300 |
| 2010 | 482 |
| 2011 | 492 |
| 2012 | 323 |
| 2013 | 240 |
| 2014 | 294 |
| 2015 | 293 |
| 2016 | 489 |
| 2017 | 546 |
| 2018 | 839 |
| 2019 | 851 |
| 2020 | 1,050 |
| 2021 | 1,534 |
| 2022 | 2,216 |
| 2023 | 2,700 |
| 2024 | 3,449 |
| 2025 | 3,227 |
| 2026 | 2,676 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,031,857 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| pancytopeniaSignal | 1,010 | 17.3 | 16.3 | 15,295 |
| malignant neoplasm progressionSignal | 1,726 | 16.1 | 15.4 | 24,220 |
| febrile neutropeniaSignal | 799 | 11.5 | 10.7 | 7,570 |
| disease progressionSignal | 1,147 | 9.2 | 8.7 | 8,365 |
| thrombocytopeniaSignal | 997 | 8.5 | 8.0 | 6,542 |
| neutropeniaSignal | 1,071 | 7.5 | 7.1 | 5,997 |
| anaemiaSignal | 1,313 | 6.5 | 6.2 | 6,158 |
| acute kidney injurySignal | 840 | 5.2 | 4.9 | 2,850 |
| pneumoniaSignal | 800 | 2.3 | 2.2 | 616 |
| vomiting | 823 | 1.7 | 1.5 | 216 |
| diarrhoea | 1,041 | 1.5 | 1.4 | 191 |
| nausea | 1,071 | 1.3 | 1.2 | 66 |
| off label use | 1,130 | 1.2 | 1.2 | 45 |
| death | 797 | 0.9 | 0.8 | 15 |
| drug ineffective | 983 | 0.7 | 0.7 | 131 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.